Azucena EsparÃ-s-Ogando

List of Publications by Year
in descending order

38 papers	2,116 citations	218381 26 h-index	329751 37 g-index
38 all docs	38 docs citations	38 times ranked	2833 citing authors

#	Article	IF	Citations
1	Extracellular Signal-regulated Kinase Phosphorylates Tumor Necrosis Factor Î±-converting Enzyme at Threonine 735: A Potential Role in Regulated Shedding. Molecular Biology of the Cell, 2002, 13, 2031-2044.	0.9	273
2	Erk5 Participates in Neuregulin Signal Transduction and Is Constitutively Active in Breast Cancer Cells Overexpressing ErbB2. Molecular and Cellular Biology, 2002, 22, 270-285.	1.1	163
3	Differential Shedding of Transmembrane Neuregulin Isoforms by the Tumor Necrosis Factor-Î±-Converting Enzyme. Molecular and Cellular Neurosciences, 2000, 16, 631-648.	1.0	152
4	Expression of Erk5 in Early Stage Breast Cancer and Association with Disease Free Survival Identifies this Kinase as a Potential Therapeutic Target. PLoS ONE, 2009, 4, e5565.	1.1	99
5	Neuregulins and Cancer. Clinical Cancer Research, 2008, 14, 3237-3241.	3.2	95
6	Cellular Plasticity Confers Migratory and Invasive Advantages to a Population of Glioblastoma-Initiating Cells that Infiltrate Peritumoral Tissue. Stem Cells, 2013, 31, 1075-1085.	1.4	83
7	Multifunctional role of Erk5 in multiple myeloma. Blood, 2005, 105, 4492-4499.	0.6	82
8	Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer. Oncogene, 2014, 33, 148-156.	2.6	78
9	Activation of ErbB2 by Overexpression or by Transmembrane Neuregulin Results in Differential Signaling and Sensitivity to Herceptin. Cancer Research, 2005, 65, 6801-6810.	0.4	63
10	Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer. Journal of Experimental and Clinical Cancer Research, 2019, 38, 383.	3.5	62
11	Stimulation of cleavage of membrane proteins by calmodulin inhibitors. Biochemical Journal, 2000, 346, 359-367.	1.7	59
12	Bortezomib is an efficient agent in plasma cell leukemias. International Journal of Cancer, 2005, 114, 665-667.	2.3	59
13	The mitogen-activated protein kinase ERK5 regulates the development and growth of hepatocellular carcinoma. Gut, 2015, 64, 1454-1465.	6.1	58
14	Synergic antitumoral effect of an IGF-IR inhibitor and trastuzumab on HER2-overexpressing breast cancer cells. Annals of Oncology, 2008, 19, 1860-1869.	0.6	57
15	Neuregulin Expression Modulates Clinical Response to Trastuzumab in Patients With Metastatic Breast Cancer. Journal of Clinical Oncology, 2007, 25, 2656-2663.	0.8	53
16	ERK5/BMK1 Is a Novel Target of the Tumor Suppressor VHL: Implication in Clear Cell Renal Carcinoma. Neoplasia, 2013, 15, 649-IN17.	2.3	53
17	Mitogen-activated protein kinase-dependent and -independent routes control shedding of transmembrane growth factors through multiple secretases. Biochemical Journal, 2002, 363, 211-221.	1.7	51
18	Targeting the EGF/HER Ligand-Receptor System in Cancer. Current Pharmaceutical Design, 2016, 22, 5887-5898.	0.9	51

#	Article	IF	Citations
19	Cleavage of the TrkA neurotrophin receptor by multiple metalloproteases generates signalling-competent truncated forms. European Journal of Neuroscience, 1999, 11, 1421-1430.	1.2	49
20	ODZ1 allows glioblastoma to sustain invasiveness through a Myc-dependent transcriptional upregulation of RhoA. Oncogene, 2017, 36, 1733-1744.	2.6	48
21	Potent Antimyeloma Activity of a Novel ERK5/CDK Inhibitor. Clinical Cancer Research, 2013, 19, 2677-2687.	3.2	45
22	Mitogen-activated protein kinase-dependent and -independent routes control shedding of transmembrane growth factors through multiple secretases. Biochemical Journal, 2002, 363, 211.	1.7	43
23	ERK2, but Not ERK1, Mediates Acquired and â€œDe novoâ€•Resistance to Imatinib Mesylate: Implication for CML Therapy. PLoS ONE, 2009, 4, e6124.	1.1	41
24	Resistance to MAPK Inhibitors in Melanoma Involves Activation of the IGF1Râ€“MEK5â€“Erk5 Pathway. Cancer Research, 2019, 79, 2244-2256.	0.4	41
25	Therapeutic potential of ERK5 targeting in triple negative breast cancer. Oncotarget, 2014, 5, 11308-11318.	0.8	40
26	Erk5 nuclear location is independent on dual phosphorylation, and favours resistance to TRAIL-induced apoptosis. Cellular Signalling, 2007, 19, 1473-1487.	1.7	29
27	Signalling-competent truncated forms of ErbB2 in breast cancer cells: differential regulation by protein kinase C and phosphatidylinositol 3-kinase. Biochemical Journal, 1999, 344, 339-348.	1.7	24
28	A Transcriptomic Immunologic Signature Predicts Favorable Outcome in Neoadjuvant Chemotherapy Treated Triple Negative Breast Tumors. Frontiers in Immunology, 2019, 10, 2802.	2.2	24
29	The Extracellular Linker of pro-Neuregulin-Î±2c Is Required for Efficient Sorting and Juxtacrine Function. Molecular Biology of the Cell, 2007, 18, 380-393.	0.9	23
30	The mitogen-activated protein kinase Erk5 mediates human mesangial cell activation. Nephrology Dialysis Transplantation, 2008, 23, 3403-3411.	0.4	23
31	Neuregulin expression in solid tumors: Prognostic value and predictive role to anti-HER3 therapies. Oncotarget, 2016, 7, 45042-45051.	0.8	21
32	Stimulation of cleavage of membrane proteins by calmodulin inhibitors. Biochemical Journal, 2000, 346, 359.	1.7	19
33	Clinical, genetic and pharmacological data support targeting the MEK5/ERK5 module in lung cancer. Npj Precision Oncology, 2021, 5, 78.	2.3	16
34	Inhibition of ERK5 Elicits Cellular Senescence in Melanoma via the Cyclin-Dependent Kinase Inhibitor p21. Cancer Research, 2022, 82, 447-457.	0.4	16
35	MEK5 promotes lung adenocarcinoma. European Respiratory Journal, 2019, 53, 1801327.	3.1	10
36	Signalling-competent truncated forms of ErbB2 in breast cancer cells: differential regulation by protein kinase C and phosphatidylinositol 3-kinase. Biochemical Journal, 1999, 344, 339.	1.7	9

#	Article	IF	Citations
37	Overexpression of RasN17 Fails to Neutralize Endogenous Ras in MCF7 Breast Cancer Cells. Journal of Biochemistry, 2005, 137, 731-739.	0.9	4
38	Abstract 2830: Multikinase inhibition by TG02 is therapeutically effective in two forms of breast cancer. , 2012, , .		0